Discuss your analysis

SPECIALIST PHARMACEUTICAL CONTRACT LABORATORY

Pharmaceutical Particle Analysis & Raman Identification Services

Pharmaceutical Particle Analysis & Raman Identification Services

Bring us your particle question, sample matrix and intended use. We scope identification, population analysis, comparative studies, method development and validation around the decisions your evidence needs to support.

Discuss your particle investigation

Direct scientific contact · NDA available · Controlled sample handling. Project timelines are agreed during scoping and documented in the quotation.

Analytical services

Particle Identification & Foreign Particle InvestigationIdentify an unknown particle and investigate possible sources.

We identify individual unknown particles and investigate foreign matter in pharmaceutical products, raw materials, packaging and process samples. Where appropriate, we compare findings with suitable reference spectra or customer-supplied materials to assess probable sources and guide further investigation.

Quantitative Particle Population AnalysisMeasure particle counts, size distributions and morphology.

Automated optical imaging detects and counts particles and measures size distributions and calibrated 2D morphology. Concentration is reported where sampling and preparation support it.

Particle-level Raman spectroscopy classifies defined subsets using suitable references and classification criteria. Successful assignment depends on the material, matrix and spectral quality. Material-specific population estimates are reported only when the study design supports them.

Automated particle Raman technology →DeepMorph™ image-guided targeting →

Comparative Particle StudiesDetermine how particle populations differ between samples.

Compare formulations, Test and Reference products, manufacturing lots, materials, suppliers, components or selected process conditions. We compare size distributions, morphology and chemically characterized subsets within the agreed study design. For suitable formulations, MDRS can support ingredient-specific particle characterization.

Method Development & Validation

Develop and validate an analytical method for your product and intended use.

SizeID.bio develops and validates product-specific analytical methods. We tailor controlled, low-background sample preparation, matrix treatment, membrane filtration, microscopic counting and selected-particle Raman analysis to the analytical question.

Development and validation address preparation background, particle recovery, preparation effects and analytical performance, using an agreed protocol and predefined acceptance criteria.

For difficult-to-inspect parenterals, methods can support supplemental destructive testing and lifecycle investigations.

Feasibility studies help define the approach. Where scientifically appropriate, placebo or surrogate material can support development; verification and validation address the intended product and use.

Discuss your method development and validation requirements

What you receive

Receive the agreed analytical results and raw data, with appropriate particle images and spectra. Our scientists interpret the evidence, explain relevant differences and limitations, and provide a report with technical and independent quality review.

Why pharmaceutical teams choose SizeID.bio

Work with scientists →

Discuss formulation, product quality and particle evidence with the scientists interpreting your study.

Agree confidentiality

Arrange an NDA and suitable information-sharing routes before exchanging sensitive material.

Keep evidence reviewable →

Document sample custody and provide agreed study records for customer quality review or audit.

Commit to agreed deadlines

Project timelines are agreed during scoping and documented in the quotation.

How your project works

01 Discuss the question confidentially

Tell us about the product, the finding and the decision you need to make. We can arrange an NDA before you share confidential details.

02 Agree scope, quotation and timing

Agree milestones, start conditions and the deliverable. Project timelines are agreed during scoping and documented in the quotation.

03 Ship and register samples

Coordinate shipment and receipt. We document sample identity and custody, and store accepted samples under agreed conditions.

04 Analyze and discuss findings

We measure agreed samples, compare suitable references and interpret results. We discuss material limitations, progress and proposed scope changes with you.

05 Receive reviewed evidence

We discuss the findings with you and document sample retention, feasible return or controlled disposal.

Frequently asked questions

What do you need from us to prepare a proposal?

Tell us what product or sample you have, what particle problem you are investigating, what is known so far and what decision the study should support. Formulation and matrix information, sample quantity, suspected materials or reference spectra, and your required reporting deadline help us define the scope and prepare a quotation.

Can we discuss our project under an NDA?

Yes. We can arrange an NDA before exchanging confidential formulation, product, manufacturing or investigation information. Scope and authorized information-sharing routes are agreed before sensitive material is transferred.

How do you manage and store our samples?

We coordinate agreed shipment and receipt arrangements, record sample identity and custody, and store accepted samples under agreed conditions. At project close, remaining material can be retained for an agreed period, returned where feasible or disposed of under controlled procedures. Special logistics or storage requirements are checked before sample acceptance.

Can you develop a method with placebo or surrogate material to conserve drug product?

Where scientifically appropriate, we can use placebo or a representative surrogate during method development to reduce consumption of valuable product. Whether this is suitable depends on the analytical question and whether the surrogate reflects the relevant formulation and matrix characteristics. The actual drug product may still be necessary for verification or validation.

Can you use our reference libraries or provide data for our systems?

We can evaluate suitable customer-supplied spectra and material references for use in Raman classification and source-comparison studies. Agreed results, images, spectra and particle metadata can be supplied in structured formats for your systems. Automated LIMS or database interfaces require separate technical and contractual agreement.

How do you support customer audits and pharmaceutical quality requirements?

We document sample handling, analytical procedures, measurement records, raw-data retention, technical review and quality oversight. Relevant study records and quality information can be made available under agreed audit and confidentiality arrangements. We understand the CMC and investigation context, but this does not imply GMP certification, regulatory approval or routine batch-release testing.

What if we need results urgently?

Project timelines are agreed during scoping and documented in the quotation. We assess the sample, method, logistics and laboratory capacity. We define when work starts and whether a milestone covers preliminary findings, an agreed data package or the final reviewed report.

How are your analytical services priced?

We prepare a project-specific quotation describing the analytical scope, deliverables, delivery milestone and price. Where useful, feasibility, method development and the main analytical study can be quoted as separate phases so you can decide on subsequent work based on the evidence obtained. Additional work is discussed and agreed rather than silently added.

Discuss your particle investigation

Tell us what you know about your sample and the decision the analysis should support. We can discuss feasibility, an NDA before confidential details are shared, and an express deadline if your investigation is urgent.

Discuss your particle investigation

Discuss your particle investigation